

176P Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy

M. Altini¹, I. Massa², W. Balzi¹, N. Gentili³, F. Foca², V. Danesi², S. Manunta⁴, M.A. Burgio⁴, P. Cravero⁴, F. Ejzykowicz⁵, S. Chandwani⁵, A. Delmonte⁶

¹Health Care Direction, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ²Biostatistics and Clinical Trial Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ³IT Service, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ⁴Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ⁵CORE Oncology, Merck, Rahway, NJ, USA, ⁶Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST), IRCCS, Meldola, Italy

Background: This study sought to describe treatment patterns in terms of real world first-line (1L) and second-line (2L) treatment of metastatic non-small cell lung cancer (NSCLC) prior to the availability of Immunotherapies (IOs) in Italy.

Methods: Metastatic NSCLC pts who initiated anti-cancer systemic treatment at IRST from Jan 2014 to Jun 2017 were included in this retrospective analysis based on electronic health records database, including information on demographics, clinical, tumor, molecular characteristics and treatment(s) administered.

Results: In total, 440 pts for 1L and 152 for 2L were analyzed. Median age was 69.5 and 65.9 yrs for the 1L and 2L, respectively.

Table: 176P

Pts characteristics	1L N = 440 n(%)	2L1 N = 152 n(%)
Demographics		
Age ≤ 65 yrs > 65 yrs	156 (35.5) 284 (64.5)	68 (44.7) 84 (55.3)
Gender F M	166 (37.7) 274 (62.3)	56 (36.8) 96 (63.2)
Smoking status Never Former Current Unk	38 (8.6) 200 (45.5) 119 (27.0) 83 (18.9)	15 (9.9) 80 (52.6) 43 (28.3) 14 (9.2)
Clinical		
ECOG 0-1 >2 Unknown	345 (78.4) 71 (16.1) 24 (5.5)	133 (87.5) 13 (8.6) 6 (3.9)
Stage at primary diagnosis IA-IIIb IV Unk	104 (23.7) 335 (76.1) 1 (0.2)	39 (25.7) 112 (73.7) 1 (0.7)
Histology Squamous Non Squamous Other Unk	69 (15.7) 338 (76.8) 26 (5.9) 7 (1.6)	20 (13.2) 124 (81.6) 8 (5.3) -
Molecular		
EGFR2 Wild-type Translocated Unk	279 (76.6) 51 (14.0) 34 (9.3)	113 (85.6) 15 (11.4) 4 (3.0)
ALK2 Wild-type Translocated Unk	232 (63.7) 21 (5.8) 111 (30.5)	107 (81.1) 11 (8.3) 14 (10.6)
Treatment		
Double Agent Combination Pemetrexed + Platinum ³	251 (57.0) 132 (30.0) 108 (24.6)	27 (17.8) 19 (12.5) 6 (3.9) 1 (0.7) 1 (0.7)
Gemcitabine + Platinum ³ Paclitaxel+ Carboplatin ³ Other doublets	9 (2.0) 2 (0.4) 106 (24.1) 58 (54.7)	44 (28.9) 8 (8.2) 17 (38.6) 19 (43.2)
Single Agent Chemotherapy Gemcitabine Vinorelbine Docetaxel	44 (41.5) 4 (3.8) 43 (9.8) 1 (0.2) 39 (8.9)	41 (27.0) 9 (5.9) 31 (20.4)
Targeted therapy Immunotherapy Clinical trials		

¹Pts in the 2L group were also included in 1L group.

²EGFR and ALK status are reported for pts with non-squamous and other histology (N = 364 for 1L, N = 132 for 2L)

³Platinum = cisplatin or carboplatin

Conclusions: In this real world population prior IOs approval in Italy, treatments were largely in line with NSCLC treatment guidelines. As expected, the most frequent type of regimen in 1L setting was platinum doublet and in 2L was single agent chemo.

Legal entity responsible for the study: Merck & Co., Inc.

Funding: Merck & Co., Inc.

Disclosure: F. Ejzykowicz, S. Chandwani: Employee, shareholder: Merck & Co, Inc. All other authors have declared no conflicts of interest.